Shuji Shirakawa of Kenporen Says Long-Listed Product Price Cuts Irrelevant to New Drug Development Premium

February 28, 2013
Shuji Shirakawa, Payer Representative of the CSIMC In December, the Central Social Insurance Medical Council (CSIMC), an advisory body to the health minister, recommended approving a draft interim report on NHI pricing, which includes new rules to reduce the prices...read more